Debatin K M, Goldmann C K, Bamford R, Waldmann T A, Krammer P H
Oncology/Immunology Section, University Children's Hospital, Heidelberg, FRG.
Lancet. 1990 Mar 3;335(8688):497-500. doi: 10.1016/0140-6736(90)90735-n.
The monoclonal antibody anti-APO-1 recognises a 52 kD cell membrane protein (APO-1) on some lymphoid tumour cell lines and on activated T cells. Binding of anti-APO-1 to cells expressing APO-1 results in programmed cell death, apoptosis, the most common form of death in eukaryotic cells. Expression of the antigen and sensitivity to the induction of cell death by anti-APO-1 were studied in human T-cell lines transformed by human leukaemia virus type 1 (HTLV-I) and in cultured cells from patients with adult T-cell leukaemia (ATL). APO-1 was strongly expressed on both types of cells and incubation of the cells with anti-APO-1 resulted in inhibition of proliferation and apoptosis. Induction of apoptosis may therefore be a possible therapeutic tool in HTLV-I-associated malignant disorders.
单克隆抗体抗APO-1可识别某些淋巴样肿瘤细胞系及活化T细胞上的一种52kD细胞膜蛋白（APO-1）。抗APO-1与表达APO-1的细胞结合会导致程序性细胞死亡，即凋亡，这是真核细胞中最常见的死亡形式。我们研究了1型人类白血病病毒（HTLV-I）转化的人T细胞系以及成人T细胞白血病（ATL）患者的培养细胞中该抗原的表达情况以及抗APO-1诱导细胞死亡的敏感性。两种类型的细胞上均强烈表达APO-1，用抗APO-1孵育细胞会导致增殖抑制和凋亡。因此，诱导凋亡可能是治疗HTLV-I相关恶性疾病的一种潜在治疗手段。
